Analyst: Insulet ’ s drug-delivery biz a long-term growth driver

Insulet’s (NSDQ:PODD) drug-delivery business will be a long-term growth driver for the company by as much as 20% a year for the next few years, according to Leerink Partners analysts. Billerica, Mass.-based Insulet generates 86% of its revenue from its OmniPod insulin delivery device, according to Leerink. The OmniPod technology could be easily adapted to other drugs, according to the investment bank, which cited Insulet’s partnership with Amgen (NSDQ:AMGN) as a foundation for other wearable drug-delivery products. “There are a significant number of injectable drugs that are nearing patent expiration over the next few years that could foreseeably benefit from a differentiated drug delivery system,” according to the report. “In addition to features inspired by the Neulasta agreement, we have identified complicated dosing schedules and poor drug adherence as potential attributes that could benefit from a wearable delivery device.” Get the full story at our sister site, Drug Delivery Business News. The post Analyst: Insulet’s drug-delivery biz a long-term growth driver appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Drug-Device Combinations Amgen Insulet Corp. Leerink Partners Source Type: news